Medicenna Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Medicenna Therapeutics kazanç ve gelirin sırasıyla yıllık 60.2% ve 72.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 59% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -16% olacağı tahmin edilmektedir.

Anahtar bilgiler

60.2%

Kazanç büyüme oranı

59.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	72.3%
Gelecekteki özkaynak getirisi	-16.0%
Analist kapsamı	Low
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Medicenna extends period to exercise certain warrants

Sep 30

Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment

Sep 13

Kazanç ve Gelir Büyüme Tahminleri

OTCPK:MDNA.F - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CAD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	15	-14	N/A	58	1
3/31/2026	0	-22	N/A	18	3
3/31/2025	N/A	-18	N/A	-17	3
9/30/2024	N/A	-27	-17	-17	N/A
6/30/2024	N/A	-26	-15	-15	N/A
3/31/2024	N/A	-25	-16	-16	N/A
12/31/2023	N/A	-15	-14	-14	N/A
9/30/2023	N/A	-12	-13	-13	N/A
6/30/2023	N/A	-9	-14	-14	N/A
3/31/2023	N/A	-10	-13	-13	N/A
12/31/2022	N/A	-9	-13	-13	N/A
9/30/2022	N/A	-13	-16	-16	N/A
6/30/2022	N/A	-20	-21	-21	N/A
3/31/2022	N/A	-23	-24	-24	N/A
12/31/2021	N/A	-25	-23	-23	N/A
9/30/2021	N/A	-26	-20	-20	N/A
6/30/2021	N/A	-21	-17	-17	N/A
3/31/2021	N/A	-17	-15	-15	N/A
12/31/2020	N/A	-14	-16	-16	N/A
9/30/2020	N/A	-11	-14	-14	N/A
6/30/2020	N/A	-9	-5	-5	N/A
3/31/2020	N/A	-8	-5	-5	N/A
12/31/2019	N/A	-7	-5	-5	N/A
9/30/2019	N/A	-6	-5	-5	N/A
6/30/2019	N/A	-5	-8	-8	N/A
3/31/2019	N/A	-5	-8	-8	N/A
12/31/2018	N/A	-5	-9	-9	N/A
9/30/2018	N/A	-5	-10	-10	N/A
6/30/2018	N/A	-6	N/A	-11	N/A
3/31/2018	N/A	-7	N/A	-10	N/A
12/31/2017	N/A	-11	N/A	-10	N/A
9/30/2017	N/A	-11	N/A	-8	N/A
6/30/2017	N/A	-10	N/A	-8	N/A
3/31/2017	N/A	-8	N/A	-7	N/A
12/31/2016	N/A	-3	N/A	-6	N/A
9/30/2016	N/A	-2	N/A	-5	N/A
6/30/2016	N/A	-1	N/A	-4	N/A
3/31/2016	N/A	-1	N/A	-3	N/A
3/31/2015	N/A	-1	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MDNA.F önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: MDNA.F önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: MDNA.F önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: MDNA.F şirketinin gelirinin (yıllık 72.3% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MDNA.F şirketinin gelirinin (yıllık 72.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MDNA.F 3 yıl içinde kârsız olması bekleniyor.

Medicenna Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 8.9% to US$5.83

Price target decreased to US$7.00

No longer forecast to breakeven

Price target decreased to US$8.40

Price target increased to US$10.50

Forecast to breakeven in 2025

Recent updates

Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

Price target decreased by 8.9% to US$5.83

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

High number of new and inexperienced directors

Medicenna Therapeutics Corp. Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 Ability Study of Mdna11 At the Sitc Annual Meeting

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Lead Independent Director recently bought US$54k worth of stock

Medicenna extends period to exercise certain warrants

Medicenna Therapeutics Corp. Confirms Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Presents Preclinical Data Demonstrating Anti-Tumor Activity of Its Anti-Pd1-Il-2 Biskit and Long-Acting Il-4/Il-13 Super-Antagonist At Cytokines 2022

Medicenna Therapeutics Corp. Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment

Price target decreased to US$7.00

Medicenna Therapeutics GAAP EPS of -$0.07 in-line

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics stock slides on launch of units offering

Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp., Annual General Meeting, Sep 21, 2022

No longer forecast to breakeven

Price target decreased to US$8.40

Price target increased to US$10.50

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting

Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 Ability Study

High number of new and inexperienced directors

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

Forecast to breakeven in 2025

Price target decreased to US$9.20

Medicenna Therapeutics Corp. Announces Management Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Medicenna Therapeutics Corp. to Report Q3, 2022 Results on Feb 09, 2022

Medicenna Therapeutics Corp. Announces Board Appointments

Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer

Medicenna Therapeutics Corp. Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with Mdna11 Treatment in the Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada